Clinical trial · Observational
Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Prospective Study on the Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is the most common malignant tumor in women worldwide,and there exist a large part of patients need to receive neoadjuvant chemotherapy(NAC) before the curative surgery.Circulating tumor DNA(ctDNA) is the circulating free DNA in the blood that originates from cancers,and it can be detected by modern technologies in plasma.In this prospective study,investigators aim to observe the correlation between tumor response to neoadjuvant chemotherapy and ctDNA.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Circulating Tumor DNA | Breast Neoplasm | PROBABILISTIC | 0.70 |
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- dynamic changes of plasma ctDNA mutant copies by a panel of 363 cancer-related genes
- timeFrame
- From patients recruited into the research until the surgury complete ,assessed up to 26 weeks.
- description
- To assess the changes of ctDNA mutant copies during the process of our observation,and to find out the relationship between ctDNA and tumor response to neoadjuvant chemotherapy
Secondary outcomes (1)
- measure
- disease free survival after surgery
- timeFrame
- Up to 5 years
- description
- To observe the duration from the end of curative surgery to local recurrence or distant metastasis of breast cancer. Patients were followed up every six months in first three years, then followed up once a year.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients undergoing neoadjuvant chemotherapy * Age: 18-70 yrs * Any menopausal status * Any hormone receptor status * Invasive breast cancer proven histologically at diagnosis (before neoadjuvant chemotherapy): * Locally advanced tumor * Patients who received 6 to 8 cycles of neoadjuvant chemotherapy. Exclusion Criteria: * Failed to retain blood sample before NAC * Lost more than 2 blood samples during NAC
References
Publications (0)
Data not yet available